
    
      Pembrolizumab is FDA approved and commercially available for treatment of many types of
      cancers. It is considered investigational to use chemotherapy combined with pembrolizumab to
      treat thymoma or Thymic carcinoma.

      Subjects will be evaluated for eligibility during a 28-day screening period. Eligible
      subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab.
      Response rate assessed by the site investigators according to the Response Evaluation
      Criteria In Solid Tumors (RECIST v1.1).

      Up to 40 participants will be enrolled in this study.
    
  